Breakthrough with 'first Huntington's drug to slow disease'
Development hailed as 'groundbreaking'
Monday, 11th December 2017

Scientists have for the first time fixed a protein defect that causes Huntingdon's disease.
Researchers injected a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.
The success in the early-stage clinical trial has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of US$45 million.
Lead researcher Sarah Tabrizi, professor of clinical neurology at University College London, said the ability of the drug to tackle the underlying cause of Huntingdon's by lowering levels of a toxic protein was "groundbreaking".
"The key now is to move quickly to a larger trial to test whether IONIS-HTT(Rx) slows disease progression," she said in a statement on Monday.
Huntingdon's is a progressive neurodegenerative disease affecting mental abilities and physical control that normally hits sufferers between the ages of 30 and 50 years before continually worsening over a 10- to 25-year period.
There is currently no effective disease-modifying treatment for the condition, with existing medicines focused only on managing disease symptoms.
Latest
- T&T: Soca icon Iwer George publicly endorses UNC, a week bef...
-
Over 30 false killer whales stranded in Belize's Drown Caye,... -
St Kitts and Nevis closes record-breaking cruise season as I... -
Antiguan Zonique Charles wins gold with 46.29m javelin throw... -
Vatican in shock: Pope Francis dies on Easter Monday at 88
Related Articles

Monday, 11th December 2017

Monday, 11th December 2017

Monday, 11th December 2017

Monday, 11th December 2017

Monday, 11th December 2017

Monday, 11th December 2017